#NewAseBioMember | “AseBio providing an unparalleled platform to collaborate with other companies in the sector”

AseBio. What does your company's work bring to the table and what is its strength?

Carlos Pérez Sánchez. Cobiomic Bioscience SL is a spin-off from the University of Córdoba and the Maimónides Institute of Biomedical Research of Córdoba (IMIBIC), formed by a multidisciplinary group of biomedical doctors, university professors, physicians, bioinformaticians, and international figures from the business sector. With over 15 years of experience in the analysis of biomarkers in chronic inflammatory diseases, supported by more than 100 scientific publications, 5 patents, and numerous international awards, we have the necessary expertise to support other researchers in the search for new tools that can drive the development of precision medicine.

On one hand, we develop models that combine molecular data from patients' blood with clinical data and artificial intelligence, generating algorithms capable of predicting therapeutic response and disease prognosis in conditions such as Rheumatoid Arthritis, Spondyloarthritis, Psoriatic Arthritis, etc.

On the other hand, we are the first Spanish core lab certified by the multinational Olink Proteomics to offer a disruptive biomarker identification service using the "proximity extension assay" technique. In just one microliter of any biological sample (blood, tears, saliva, urine, cells, etc.), we analyze 92 protein biomarkers via qPCR using antibodies linked to oligonucleotides. Currently, we have over 15 panels of 92 different proteins depending on the research area (oncology, neurology, inflammation, cardiovascular disease, etc.), which helps other researchers identify the most relevant biomarkers that can drive the development of precision medicine in any area of interest.

AseBio. What is AseBio for you?

Carlos Pérez Sánchez. For Cobiomic, AseBio is an association that represents and promotes the interests of biotechnology companies in Spain, providing an unparalleled platform to collaborate with other companies in the sector, access specialized resources, participate in events, and contribute to the growth and visibility of the biotechnology industry in the country.

AseBio. When did you first hear about AseBio?

Carlos Pérez Sánchez. We know about AseBio through social media and events and conferences where we have coincided.

AseBio. What do you expect from being part of an association like AseBio?

Carlos Pérez Sánchez. By being part of AseBio, we hope to have the opportunity to establish strategic collaborations with other companies in the biotechnology sector, access specialized resources and knowledge to help improve our capabilities and competencies, participate in initiatives and events that drive growth and innovation in our company, as well as contribute to the development and strengthening of the biotechnology industry in Spain. Additionally, we look forward to leveraging the networking and exchange of experiences that the association offers to continue growing and achieving success in the field of biotechnology.

AseBio. What is the biggest challenge facing the biotech sector (or your company)?

Carlos Pérez Sánchez. The biggest challenge in the biotechnology sector is being able to transfer all the knowledge generated in laboratories into a product that can be used in the clinical setting to improve the quality of life of patients. This process of technology transfer and development of innovative products that are safe, effective, and accessible for application in clinical practice is essential for the advancement and consolidation of biotechnology in the health and medicine sector.